Individualized Angiotensin‐Converting Enzyme (ACE)‐Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model

BACKGROUND: Patients with stable coronary artery disease (CAD) constitute a heterogeneous group in which the treatment benefits by angiotensin‐converting enzyme (ACE)‐inhibitor therapy vary between individuals. Our objective was to integrate clinical and pharmacogenetic determinants in an ultimate c...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Am Heart Assoc
Главные авторы: Oemrawsingh, Rohit M., Akkerhuis, K. Martijn, Van Vark, Laura C., Redekop, W. Ken, Rudez, Goran, Remme, Willem J., Bertrand, Michel E., Fox, Kim M., Ferrari, Roberto, Danser, A.H. Jan, de Maat, Moniek, Simoons, Maarten L., Brugts, Jasper J., Boersma, Eric
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2016
Предметы:
Original Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4943245/
https://ncbi.nlm.nih.gov/pubmed/27021566
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.115.002688
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы